IPX233-B13-01:Evaluation of the Pharmacokinetics of IPX233 Formulations in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
Price : $35 *
At a glance
- Drugs IPX 233 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors IMPAX Laboratories
- 03 Jun 2014 Status changed from not yet recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 28 Nov 2013 Planned initiation date changed from 22 Nov 2013 to 6 Dec 2013 as reported by Australian New Zealand Clinical Trials Registry record.
- 28 Sep 2013 New trial record